<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Indivior Pharmaceuticals, Inc. — News on 6ix</title>
<link>https://6ix.com/company/indivior-pharmaceuticals-inc</link>
<description>Latest news and press releases for Indivior Pharmaceuticals, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 04 May 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/indivior-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d9f227d20c3ebdd611540a.webp</url>
<title>Indivior Pharmaceuticals, Inc.</title>
<link>https://6ix.com/company/indivior-pharmaceuticals-inc</link>
</image>
<item>
<title>Indivior Announces $175 Million Accelerated Share Repurchase</title>
<link>https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-announces-dollar175-million-accelerated-share-repurchase</link>
<guid isPermaLink="true">https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-announces-dollar175-million-accelerated-share-repurchase</guid>
<pubDate>Mon, 04 May 2026 11:00:00 GMT</pubDate>
<description>RICHMOND, Va., May 04, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV), today announced that it has entered into a $175 million accelerated share repurchase agreement (“the ASR”) with Barclays Bank PLC (“Barclays”). The ASR will be executed under Indivior’s existing $400 million share repurchase program previously authorized by the Company’s Board of Directors. The ASR reflects the Company’s confidence in its long-term strategy, cash flow generation, and commitment to disc</description>
</item>
<item>
<title>Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance</title>
<link>https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-reports-first-quarter-2026-financial-results-and-raises-full-year-2026-guidance</link>
<guid isPermaLink="true">https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-reports-first-quarter-2026-financial-results-and-raises-full-year-2026-guidance</guid>
<pubDate>Thu, 30 Apr 2026 11:00:00 GMT</pubDate>
<description>Q1’26 Total Net Revenue of $317 Million, Up 19% YoYQ1’26 Total SUBLOCADE® Net Revenue of $232 Million, Up 32% YoY Q1'26 GAAP Net Income of $89 Million and Q1'26 Non-GAAP Net Income of $123 MillionRecord Quarterly Adjusted EBITDA of $164 Million in Q1'26, Up 112% YoYRepurchased Approximately Four Million Shares in Q1'26 for $125 MillionConference Call at 8:00 A.M. EDT Today RICHMOND, Va., April 30, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today reported its financial</description>
</item>
<item>
<title>Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder</title>
<link>https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-presents-new-real-world-data-at-asam-2026-annual-conference-supporting-remission-as-a-treatment-outcome-and-reinforcing-the-clinical-benefits-of-monthly-injectable-buprenorphine-for-opioid-use-disorder</link>
<guid isPermaLink="true">https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-presents-new-real-world-data-at-asam-2026-annual-conference-supporting-remission-as-a-treatment-outcome-and-reinforcing-the-clinical-benefits-of-monthly-injectable-buprenorphine-for-opioid-use-disorder</guid>
<pubDate>Fri, 24 Apr 2026 15:00:00 GMT</pubDate>
<description>A collaboration with Virginia Tech supports recognizing remission as a treatment outcome—capturing symptoms, quality of life, and functional outcomes—beyond abstinence aloneOf all MOUD, monthly extended-release buprenorphine (BUP-XR) accounted for the smallest proportion of non-fatal and fatal OD events compared to no treatment. RICHMOND, Va., April 24, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV), a leader in the treatment of opioid use disorder (OUD), will present one</description>
</item>
<item>
<title>Survey of Correctional Facility Staff: Monthly Opioid Treatment Shot May Help Reduce Medication Misuse</title>
<link>https://6ix.com/company/indivior-pharmaceuticals-inc/news/survey-of-correctional-facility-staff-monthly-opioid-treatment-shot-may-help-reduce-medication-misuse</link>
<guid isPermaLink="true">https://6ix.com/company/indivior-pharmaceuticals-inc/news/survey-of-correctional-facility-staff-monthly-opioid-treatment-shot-may-help-reduce-medication-misuse</guid>
<pubDate>Thu, 16 Apr 2026 18:30:00 GMT</pubDate>
<description>RICHMOND, Va., April 16, 2026 (GLOBE NEWSWIRE) -- Indivior PLC (Nasdaq: INDV) today announced results from a national survey published in the Journal of Correctional Health Care showing that correctional leaders identify staffing and coordination gaps as key barriers to reducing diversion of medications for opioid use disorder (MOUD) and recognized long-acting injectable (LAI) buprenorphine as a strategy to help mitigate diversion and improve treatment in jail and prison settings. The cross-sect</description>
</item>
<item>
<title>Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th</title>
<link>https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-to-report-first-quarter-2026-financial-results-and-host-webcast-on-april-30th-1</link>
<guid isPermaLink="true">https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-to-report-first-quarter-2026-financial-results-and-host-webcast-on-april-30th-1</guid>
<pubDate>Thu, 09 Apr 2026 11:00:00 GMT</pubDate>
<description>RICHMOND, Va., April 09, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its first quarter 2026 financial results on Thursday, April 30, 2026, at 7:00 a.m. U.S. EDT. Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior’s leadership team will host a presentation via live webcast at 8:00 a.m. U.S. EDT. Access to the Live Webcast Presentation: The webcast event and materials ca</description>
</item>
<item>
<title>Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th </title>
<link>https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-to-report-first-quarter-2026-financial-results-and-host-webcast-on-april-30th</link>
<guid isPermaLink="true">https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-to-report-first-quarter-2026-financial-results-and-host-webcast-on-april-30th</guid>
<pubDate>Thu, 09 Apr 2026 04:00:00 GMT</pubDate>
<description>RICHMOND, Va., April 09, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its first quarter 2026</description>
</item>
<item>
<title>New Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities</title>
<link>https://6ix.com/company/indivior-pharmaceuticals-inc/news/new-cost-impact-model-highlights-potential-for-monthly-injectable-buprenorphine-to-reduce-staffing-burdens-in-correctional-facilities</link>
<guid isPermaLink="true">https://6ix.com/company/indivior-pharmaceuticals-inc/news/new-cost-impact-model-highlights-potential-for-monthly-injectable-buprenorphine-to-reduce-staffing-burdens-in-correctional-facilities</guid>
<pubDate>Tue, 31 Mar 2026 13:00:00 GMT</pubDate>
<description>Model estimates SUBLOCADE® may reduce staff time and associated costs compared with other medications for opioid use disorder in jails and prisons RICHMOND, Va., March 31, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc., (Nasdaq: INDV) today announced findings from a new cost impact model published in The Journal of Current Medical Research and Opinion, estimating that the use of extended-release buprenorphine, a monthly injectable commercially available as SUBLOCADE®, may reduce staff t</description>
</item>
<item>
<title>National Survey Finds Only 58% of U.S. Correctional Facilities Offer Medications for Opioid Use Disorder</title>
<link>https://6ix.com/company/indivior-pharmaceuticals-inc/news/national-survey-finds-only-58percent-of-us-correctional-facilities-offer-medications-for-opioid-use-disorder</link>
<guid isPermaLink="true">https://6ix.com/company/indivior-pharmaceuticals-inc/news/national-survey-finds-only-58percent-of-us-correctional-facilities-offer-medications-for-opioid-use-disorder</guid>
<pubDate>Tue, 17 Mar 2026 16:02:00 GMT</pubDate>
<description>Jails outpace prisons in offering MOUD, but regional disparities and limited treatment access persist across the U.S.Qualitative feedback points to need for greater reentry support, housing, care coordination, and provider training RICHMOND, Va., March 17, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals Inc. (Nasdaq: INDV) announced results from a cross-sectional survey published in the Journal of Correctional Health Care that reveal critical gaps in the availability of medications for opioid</description>
</item>
<item>
<title>Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering</title>
<link>https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-prices-upsized-dollar4500-million-convertible-senior-notes-offering-21</link>
<guid isPermaLink="true">https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-prices-upsized-dollar4500-million-convertible-senior-notes-offering-21</guid>
<pubDate>Thu, 12 Mar 2026 04:00:00 GMT</pubDate>
<description>RICHMOND, Va., March 12, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced the pricing of its offering of $450,000,000</description>
</item>
<item>
<title>Indivior Announces Proposed Convertible Senior Notes Offering</title>
<link>https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-announces-proposed-convertible-senior-notes-offering-7</link>
<guid isPermaLink="true">https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-announces-proposed-convertible-senior-notes-offering-7</guid>
<pubDate>Thu, 12 Mar 2026 04:00:00 GMT</pubDate>
<description>RICHMOND, Va., March 12, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced its intention to offer, subject to market and</description>
</item>
<item>
<title>New Study Shows Adherence to Monthly Injectable Buprenorphine Linked to Lower Healthcare Utilization and Costs in Opioid Use Disorder</title>
<link>https://6ix.com/company/indivior-pharmaceuticals-inc/news/new-study-shows-adherence-to-monthly-injectable-buprenorphine-linked-to-lower-healthcare-utilization-and-costs-in-opioid-use-disorder-2</link>
<guid isPermaLink="true">https://6ix.com/company/indivior-pharmaceuticals-inc/news/new-study-shows-adherence-to-monthly-injectable-buprenorphine-linked-to-lower-healthcare-utilization-and-costs-in-opioid-use-disorder-2</guid>
<pubDate>Wed, 11 Mar 2026 13:00:00 GMT</pubDate>
<description>Patients adherent to SUBLOCADE® for 12 months had 42% lower adjusted non-MOUD medical costs vs. those adherent to other forms of MOUDPatients adherent to SUBLOCADE had the lowest inpatient, emergency department, and detoxification utilization across all treatment groups RICHMOND, Va., March 11, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals (Nasdaq: INDV) today announced findings from a new real-world evidence, retrospective observational study published in Frontiers in Public Health showing</description>
</item>
<item>
<title>Indivior Reports Fourth Quarter and Full-Year 2025 Financial Results</title>
<link>https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-reports-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
<description>Generated Record Quarterly and Full-Year Total SUBLOCADE® Net Revenue of $252 Million and $856 MillionAchieved Quarterly and Full-Year GAAP Net Income of $102</description>
</item>
<item>
<title>Indivior to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-to-participate-in-upcoming-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-to-participate-in-upcoming-investor-conferences</guid>
<pubDate>Tue, 24 Feb 2026 12:00:00 GMT</pubDate>
<description>RICHMOND, Va., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will participate in the following upcoming investor conferences: Barclays 28th Annual Global Healthcare Conference – Miami, FLJoe Ciaffoni, Chief Executive Officer, will host 1x1 / group meetings on Tuesday, March 10th. Joe Ciaffoni will also participate in a fireside chat on Tuesday, March 10th at 2:00 p.m. U.S. EST. Interested investors should contact their Barclays representa</description>
</item>
<item>
<title>Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26ᵗʰ</title>
<link>https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-to-report-fourth-quarter-and-full-year-2025-financial-results-and-host-webcast-on-february-26</link>
<guid isPermaLink="true">https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-to-report-fourth-quarter-and-full-year-2025-financial-results-and-host-webcast-on-february-26</guid>
<pubDate>Wed, 28 Jan 2026 12:00:00 GMT</pubDate>
<description>RICHMOND, Va., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its fourth quarter and full-year 2025 financial results on Thursday, February 26, 2026, at 7:00 a.m. U.S. EST. Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior’s leadership team will host a presentation via live webcast at 8:00 a.m. U.S. EST. Access to the Live Webcast Presentation: The webcast event</description>
</item>
<item>
<title>Indivior Announces Completion of Redomiciliation to the United States</title>
<link>https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-announces-completion-of-redomiciliation-to-the-united-states</link>
<guid isPermaLink="true">https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-announces-completion-of-redomiciliation-to-the-united-states</guid>
<pubDate>Mon, 26 Jan 2026 05:00:00 GMT</pubDate>
<description>RICHMOND, Va., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV), today announced completion of its redomiciliation from the</description>
</item>
<item>
<title>Indivior Provides Full-Year 2026 Financial Guidance and Business Update</title>
<link>https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-provides-full-year-2026-financial-guidance-and-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-provides-full-year-2026-financial-guidance-and-business-update</guid>
<pubDate>Thu, 08 Jan 2026 05:00:00 GMT</pubDate>
<description>Total Net Revenue Expected in the Range of $1,125 million to $1,195 millionTotal SUBLOCADE® Net Revenue Expected to be in the Range of $905 million to $945</description>
</item>
<item>
<title>Indivior Announces Inclusion in the S&P SmallCap 600® Index</title>
<link>https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-announces-inclusion-in-the-sandp-smallcap-600r-index</link>
<guid isPermaLink="true">https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-announces-inclusion-in-the-sandp-smallcap-600r-index</guid>
<pubDate>Mon, 22 Dec 2025 05:00:00 GMT</pubDate>
<description>RICHMOND, Va., Dec. 22, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) ("Indivior PLC" or the "Company") today announced that it will be added to the S&P</description>
</item>
<item>
<title>New Study Shows Extended-Release Buprenorphine Safely Delivers Rapid, Clinically Meaningful Reductions in Opioid Use and Supports Abstinence in High-Risk Populations</title>
<link>https://6ix.com/company/indivior-pharmaceuticals-inc/news/new-study-shows-extended-release-buprenorphine-safely-delivers-rapid-clinically-meaningful-reductions-in-opioid-use-and-supports-abstinence-in-high-risk-populations</link>
<guid isPermaLink="true">https://6ix.com/company/indivior-pharmaceuticals-inc/news/new-study-shows-extended-release-buprenorphine-safely-delivers-rapid-clinically-meaningful-reductions-in-opioid-use-and-supports-abstinence-in-high-risk-populations</guid>
<pubDate>Wed, 17 Dec 2025 16:30:00 GMT</pubDate>
<description>Indivior PLC (Nasdaq: INDV) today announced results from a randomized, double-blind clinical trial published in JAMA Network Open. The study found that both the 100-mg and 300-mg monthly maintenance doses of SUBLOCADE® (extended-release buprenorphine) rapidly reduced opioid use and improved opioid abstinence and were well tolerated, with no new safety signals in individuals with moderate-to-severe opioid use disorder (OUD). Participants across both dose groups experienced a rapid reduction in op</description>
</item>
<item>
<title>Indivior Concludes Legacy U.S. Department of Justice Matter</title>
<link>https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-concludes-legacy-us-department-of-justice-matter</link>
<guid isPermaLink="true">https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-concludes-legacy-us-department-of-justice-matter</guid>
<pubDate>Thu, 20 Nov 2025 21:01:00 GMT</pubDate>
<description>Indivior PLC (Nasdaq: INDV) today announced the Company has concluded the legacy U.S. Department of Justice (DOJ) matter by paying in full the outstanding obligation of $295 million associated with the matter. With the DOJ's receipt of the payment, the resolution agreement with the DOJ will be terminated. The payment was funded with Indivior's cash on hand.</description>
</item>
<item>
<title>Indivior to Participate in the Piper Sandler 37th Annual Healthcare Conference</title>
<link>https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-to-participate-in-the-piper-sandler-37th-annual-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/indivior-pharmaceuticals-inc/news/indivior-to-participate-in-the-piper-sandler-37th-annual-healthcare-conference</guid>
<pubDate>Wed, 19 Nov 2025 14:21:00 GMT</pubDate>
<description>Indivior PLC (NASDAQ: INDV) today announced that it will participate in the Piper Sandler 37th Annual Healthcare Conference:</description>
</item>
</channel>
</rss>